21269-34-1

Basic information

• Product Name: 4-HYDROXY-8-METHOXYQUINOLINE
• Synonyms: 4-HYDROXY-8-METHOXYQUINOLINE;8-METHOXYQUINOLIN-4-OL;8-Methoxy-4-quinolinol;NSC 52752;8-Methoxy-4-hydroxy quinoline
• CAS NO: 21269-34-1
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18
• EINECS: -0
• Mol File: 21269-34-1.mol

Chemical Properties

• Melting Point: 168-169 °C
• Boiling Point: 317.6 °C at 760 mmHg
• Flash Point: 145.9 °C
• Appearance: /
• Density: 1.199g/cm³
• Vapor Pressure: 0.000382mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.40±0.40(Predicted)
• CAS DataBase Reference: 4-HYDROXY-8-METHOXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-8-METHOXYQUINOLINE(21269-34-1)
• EPA Substance Registry System: 4-HYDROXY-8-METHOXYQUINOLINE(21269-34-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• Hazardous Substances Data: 21269-34-1(Hazardous Substances Data)

Usage

Chemical Properties

off White powder

InChI:InChI=1/C10H9NO2/c1-13-9-4-2-3-7-8(12)5-6-11-10(7)9/h2-6H,1H3,(H,11,12)

Upstream product

• 25165-68-8 5-[(2-methoxy-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 90-04-0 2-methoxy-phenylamine 
• 122-51-0 orthoformic acid triethyl ester 
• 2033-24-1 cycl-isopropylidene malonate 
• 28027-18-1 4-hydroxy-8-methoxyquinoline-3-carboxylic acid 
• 104007-09-2 2-[(2-methoxyphenylamino)-methylene]-malonic acid diethyl ester 
• 27568-04-3 Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate 

Downstream Products

• 42521-92-6 4,8-Dimethoxy-chinolin 
• 139399-63-6 4-bromo-8-hydroxyquinoline 
• 57334-36-8 4-chloro-8-hydroxyquinoline 
• 103028-31-5 4-bromo-8-methoxyquinoline 
• 16778-21-5 4-chloro-8-methoxyquinoline 

Relevant articles and documents

3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS

The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: wherein R1, R2 and -X-Y- have specific definitions. It also relates to the use of such a compound as reactivator of acetylcholinesterase for treating organophosphorous nerve agents poisoning; and to a process for preparing it.

INHIBITORS FOR THE TREATMENT OF CANCER AND RELATED METHODS

Some embodiments of the invention include inventive compounds. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutica

Organic optoelectronic functional material and application thereof

The invention belongs to the field of organic electroluminescent devices, and discloses an organic electroluminescent material containing a diquinolyl structure and application of the organic electroluminescent material. By using the organic electroluminescent material provided by the invention as an electron transport material, the produced device has good electron mobility and relatively-balanced current carrier transmission property, and the improvement efficiency of the device is facilitated. In addition, the organic electroluminescent material provided by the invention also can be furtherblended with a hole type main body material so as to form an exciplex; by using the exciplex as a co-subject material, the efficiency and the stability of the produced device are both improved obviously.

BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES

The present invention deals with novel compounds which are reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use in the treatment of a nervous and/or respiratory failure due to intoxication with a

Synthesis and anti-tumor activities of 4-anilinoquinoline derivatives

Twenty-two 7-fluoro (or 8-methoxy)-4-anilinoquinolines compounds were designed and synthesized as potentially potent and selective antitumor inhibitors. All the prepared compounds were evaluated for their in vitro antiproliferative activities against the HeLa and BGC823 cell lines. Ten compounds (1a-g; 2c; 2e and 2i) exhibited excellent antitumor activity superior to that of gefitinib. Among the ten compounds; seven (1a-c; 1e-1g and 2i) displayed excellent selectivity for BGC823 cells. In particular; 1f and 2i exhibited potent cytotoxic activities against HeLa cells and BGC823 cells with better IC50 values than gefitinib.

SELECTIVE PFKFB4 INHIBITORS FOR THE TREATMENT OF CANCER

Methods and pharmaceutical compositions for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) and the treatment of cancer are described.

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl) amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease

The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated strongly because of generation of oxidative stress leading to dopamine cell death. In our overall goal to develop bifunctional/multifunctional drugs, we designed dopamine D2/D3 agonist molecules with a capacity to bind to iron. Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptor with tritiated spiperone to evaluate inhibition constants (K i). Functional activity of selected compounds was carried out with GTPyS binding assay. SAR results identified compounds (+)-19a and (-)-19b as two potent agonists for both D2 and D3 receptors (EC50 (GTPyS); D2 = 4.51 and 1.69 nM and D3 = 1.58 and 0.74 nM for (-)-19b and (+)-19a, respectively). In vitro complexation studies with 19b demonstrated efficient chelation with iron. Furthermore, the deoxyribose assay with 19b demonstrated potent antioxidant activity. In PD animal model study, (-)-19b exhibited potent in vivo activity in reversing locomotor activity in reserpinized rats and also in producing potent rotational activity in 6-OHDA lesioned rats. This reports initial development of unique lead molecules that might find potential use in symptomatic and neuroprotective treatment of PD.

Thioquinolone compounds which have useful pharmaceutical activity

Disclosed is a thioquinolone derivative which exhibits highly selective antibacterial activity against Helicobacter pylori.